Myriad Genetics, Inc. (MYGN)’s debt-to-equity and long-term debt/equity ratios

As of close of business last night, Myriad Genetics, Inc.’s stock clocked out at $20.00, down -6.72% from its previous closing price of $21.44. In other words, the price has decreased by -$1.44 from its previous closing price. On the day, 705425 shares were traded.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Ratios:

To gain a deeper understanding of MYGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.87 and its Current Ratio is at 2.01. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.

On December 19, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.

On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $23.Guggenheim initiated its Buy rating on December 14, 2023, with a $23 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’23 when Riggsbee Richard Bryan sold 30,000 shares for $19.09 per share. The transaction valued at 572,835 led to the insider holds 291,812 shares of the business.

Riggsbee Richard Bryan sold 30,000 shares of MYGN for $470,622 on Nov 01 ’23. The Chief Financial Officer now owns 321,812 shares after completing the transaction at $15.69 per share. On Jun 02 ’23, another insider, SPIEGELMAN DANIEL K, who serves as the Director of the company, sold 8,638 shares for $23.01 each. As a result, the insider received 198,760 and left with 40,493 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1.93B and an Enterprise Value of 1.94B. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.39 while its Price-to-Book (P/B) ratio in mrq is 2.30. Its current Enterprise Value per Revenue stands at 2.57 whereas that against EBITDA is -9.82.

Stock Price History:

Over the past 52 weeks, MYGN has reached a high of $24.21, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is 22.10, while the 200-Day Moving Average is calculated to be 19.47.

Shares Statistics:

It appears that MYGN traded 645.54K shares on average per day over the past three months and 592.1k shares per day over the past ten days. A total of 89.90M shares are outstanding, with a floating share count of 85.66M. Insiders hold about 4.69% of the company’s shares, while institutions hold 101.36% stake in the company. Shares short for MYGN as of Mar 15, 2024 were 4.8M with a Short Ratio of 7.44, compared to 3.7M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.34% and a Short% of Float of 7.38%.

Earnings Estimates

As of right now, 12 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.1 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.18, while EPS last year was -$0.21. The consensus estimate for the next quarter is $0, with high estimates of $0.03 and low estimates of -$0.02.

Analysts are recommending an EPS of between $0.07 and -$0.02 for the fiscal current year, implying an average EPS of $0.02. EPS for the following year is $0.24, with 13 analysts recommending between $0.38 and $0.03.

Revenue Estimates

In the current quarter, 12 analysts expect revenue to total $193.26M. It ranges from a high estimate of $196.32M to a low estimate of $190.36M. As of the current estimate, Myriad Genetics, Inc.’s year-ago sales were $181.2M, an estimated increase of 6.70% from the year-ago figure.

A total of 13 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $833.2M, while the lowest revenue estimate was $810.15M, resulting in an average revenue estimate of $826.67M. In the same quarter a year ago, actual revenue was $753.2M, up 9.80% from the average estimate. Based on 13 analysts’ estimates, the company’s revenue will be $894.78M in the next fiscal year. The high estimate is $914.32M and the low estimate is $860.19M. The average revenue growth estimate for next year is up 8.20% from the average revenue estimate for this year.

Most Popular